Glytec announced today that it entered into a strategic partnership with Roche Diagnostics USA for a digital health collaboration.
Waltham, Massachusetts-based Glytec’s partnership combines its FDA-cleared Glucommander insulin dosing decision support software with Roche’s expertise in medical devices and IT solutions in an effort to address the challenges associated with inpatient blood sugar management at the hospital bedside.
According to a news release, Glucommander will be the first software application available on Roche’s Cobas Pulse smart-device, next-generation hospital blood glucose system.
“Our algorithmic decision support software has been helping hospital clinicians optimize glycemic management for nearly two decades, and we’ve seen the positive impact it can have,” Glytec CEO Ed Furlong said in the release. “The fact that Roche understands the importance of inpatient glycemic management and chose Glytec as the first software partner for the revolutionary device it’s designing speaks volumes about the technology we’ve built and the direction the market is headed.”
Roche designed Cobas Pulse to improve patient safety and care by empowering point-of-care clinicians to collect and take immediate action on glycemic management data. The combination of hardware and software brings together the immediacy of a bedside blood glucose test with Glytec’s insulin decision support on a single, handheld device to streamline workflows and save time.
“Diagnostics play a critical role in helping people live longer and healthier lives and we are hopeful that this partnership with Glytec will bring an innovative glucose management tool to the point of care,” Roche Diagnostics SVP of Core Lab & Point of Care Brad Moore said. “Our goal is to drive better care for patients and there is a great need for a diagnostic ecosystem that combines accurate results, robust data, and digital capabilities to improve the standard of care.”
